What happens after you ask us to watch a drug?

What do you need to tell us?

Name the drugs, molecules, competitors, or companies you follow; the decisions you are making; and the changes you care about most. You can start with one drug. The intake asks for your preferred weekly or monthly report cadence. Share public asset names only; the form is not a place for confidential plans.

See the coverage-check questions →

What does the free coverage check show?

We match each named asset to relevant public records, including alternate names and other brands of the same molecule. The check identifies which sources have useful records, which do not, and how often those sources publish. A watch is scoped to the assets and sources that matter to your question; the full source directory is not a promise that every source covers every drug.

After that check, we quote the watch for the agreed assets, sources, and cadence. You can see the scope before committing.

What will the team receive?

Every week or month, the What changed report identifies qualifying updates, explains why each is relevant to your watched asset, and links to the original record. It distinguishes a brand-specific event from evidence about a molecule shared by several brands. The report shows source and check dates, so a quiet period does not get mistaken for proof that nothing happened.

• What changed: the new finding and, where possible, the before-and-after record.
• Why it matters: the connection to the drug and question being watched.
• Where to verify it: a link to the source and its publication or check date.

Read the dated Zepbound What changed sample →

When do priority alerts arrive?

Alerts are optional and are set around the kinds of changes your team considers urgent, such as a trial status move or a label revision. They supplement the agreed report cadence. The timing depends on when the source publishes and when a matching record can be verified; periodic datasets do not become live feeds because they are in a watch.

What could an alert contain?

If FDA label changes were on your priority list, a finding could read: “Zepbound’s label published September 2, 2026 added section 5.8 on diabetic retinopathy complications; its indications did not change.” It would point to the DailyMed label and identify this as a Zepbound brand-level change. This is an illustration using the checked sample, not an alert sent to a customer.

What if no qualifying change appears?

The report can say that no qualifying update was found in the checked sources for that period, with the check dates and any gaps visible. It does not claim that nothing happened anywhere or that every public source published new data during the window.

Should you order one report or start a watch?

Choose a fixed-price, one-drug report when you need a current assessment once. Choose monitoring when you need the same assets checked again and a recurring account of what changed. A report price is credited toward a monitoring subscription started within 60 days, as described on the reports page.